1604665
USP
Risperidone System Suitability Mixture
United States Pharmacopeia (USP) Reference Standard
Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
About This Item
UNSPSC Code:
41116107
NACRES:
NA.24
Doporučené produkty
grade
pharmaceutical primary standard
API family
risperidone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
General description
Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
Application
Risperidone System Suitability Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
related product
Č. produktu
Popis
Stanovení ceny
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk_germany
WGK 3
Vyberte jednu z posledních verzí:
Osvědčení o analýze (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.
Potřebujete-li pomoc, obraťte se na Zákaznická podpora
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG
The New England Journal of Medicine, 346(1), 16-22 (2002)
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Kapur S
Life Sciences, 57(10), PL103-PL107 (1995)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G
Journal of Clinical Psychopharmacology, 13(1), 25-40 (1993)
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H
The Journal of Clinical Psychiatry, 64(2), 134-143 (2003)
Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..
Obraťte se na technický servis.